Przejdź do zawartości
Merck

Przejdź do

217708

ML141

≥99% (HPLC), solid, Cdc42/Rac1 GTPase inhibitor, Calbiochem®

Synonim(y):

Cdc42/Rac1 GTPase Inhibitor, ML141, CDC42 GTPase Inhibitor II, CDC42 Inhibitor II, Rac1 Inhibitor V, Rac1 GTPase Inhibitor II, CID2950007, (±)-4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl))-benzenesulfonamide, (±)-4-(4,5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyra, CDC42 GTPase Inhibitor II, CDC42 Inhibitor II, Rac1 Inhibitor V, Rac1 GTPase Inhibitor II, CID2950007, (±)-4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl))-benzenesulfonamide, (±)-4-(4,5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyraz

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok
Gabaryty przesyłkiSKUDostępnośćCena netto

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C22H21N3O3S
Numer CAS:
Masa cząsteczkowa:
407.49
UNSPSC Code:
12352200
NACRES:
NA.28
MDL number:
Assay:
≥99% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
Produkt 217708 nie jest obecnie dostępny w sprzedaży w Twoim kraju Skontaktuj się z zespołem ds. pomocy technicznej
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc


Nazwa produktu

Cdc42/Rac1 GTPase Inhibitor, ML141, The Cdc42/Rac1 GTPase Inhibitor, ML141 controls the biological activity of Cdc42/Rac1 GTPase. This small molecule/inhibitor is primarily used for Membrane applications.

Quality Level

assay

≥99% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

yellow-white

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

−20°C

InChI

1S/C22H21N3O3S/c1-28-19-11-7-17(8-12-19)22-15-21(16-5-3-2-4-6-16)24-25(22)18-9-13-20(14-10-18)29(23,26)27/h2-14,22H,15H2,1H3,(H2,23,26,27)

InChI key

QBNZBMVRFYREHK-UHFFFAOYSA-N

General description

A cell-permeable, allosteric, trisubstituted dihydropyrazolyl compound that acts as a potent, selective, reversible and non-competitive inhibitor of Cdc42 GTPases (IC50 = 0.2, 2.6 and 5.4 µM against nucleotide depleted Cdc42-wt, Cdc42-wt and Cdc42 activated mutant, respectively) with excellent selectivity over Rho family GTPases (IC50 >100 µM for Ras-wt, Ras activated mutant, Rab7-wt, Rab2a-wt, Rac1-wt and Rac1 activated mutant). Shown to efficiently block Cdc42 association with GTPγS and PAK-PBD, and decrease GTP-Cdc42 (>95%) and GTP-Rac1 (≥40%) contents in EGF-stimulated 3T3 cells, and inhibit Bradykinin (Cat. No. . 05-23-0500)-induced filopodia formation in 3T3 cells at 10 µM.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Hong, L., et al. 2012. J. Biol. Chem.in press.
Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.2010 Feb 27. (http://www.ncbi.nlm.nih.gov/books/NBK51965/)

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)
Ta strona może zawierać tekst przetłumaczony maszynowo.


Still not finding the right product?

Explore all of our products under


Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów



Chang Liu et al.
Acta biomaterialia, 155, 167-181 (2022-11-13)
3D in vitro tumor models have recently been investigated as they can recapitulate key features in the tumor microenvironment. Reconstruction of a biomimetic scaffold is critical in these models. However, most current methods focus on modulating local properties, e.g. micro-
Meiwan Cao et al.
Redox report : communications in free radical research, 27(1), 167-175 (2022-08-09)
The number of neutrophils is significantly reduced in myelodysplastic syndrome (MDS), but the molecular basis remains unclear. We recently found that miR-34a was significantly increased in MDS neutrophils. Therefore, this study aims to clarify the effects of aberrant miR-34a expression
Golnaz Morad et al.
International journal of molecular sciences, 21(11) (2020-06-03)
Breast cancer brain metastasis is a major clinical challenge and is associated with a dismal prognosis. Understanding the mechanisms underlying the early stages of brain metastasis can provide opportunities to develop efficient diagnostics and therapeutics for this significant clinical challenge.



Numer pozycji handlu globalnego

SKUNUMER GTIN
217708-25MG04055977202366

Questions

Reviews

No rating value

Active Filters